The global dermatology market is projected to rise from $21.1 billion to $34.0 billion by 2030, growing at an 8.6% compound annual rate. Acne treatment is also expanding, with an expected 7.4% CAGR through 2033. This article connects those market shifts to condition prevalence, provider capacity, and real-world patient behavior that shape care delivery.
Key Takeaways
- 8.6% compound annual growth rate expected for the global dermatology market from 2024 to 2030
- $21.1 billion global dermatology market size in 2023
- $34.0 billion projected global dermatology market size by 2030
- 8.1% of the global population is estimated to have acne vulgaris (2010/2015 global burden estimates)
- Psoriasis affects approximately 2% of the world’s population (global estimate)
- Eczema (atopic dermatitis) affects about 15–20% of children and 1–3% of adults worldwide (review estimates)
- A 2019 systematic review reported that moisturizers reduce signs of atopic dermatitis in children (meta-analysis outcome)
- A 2021 meta-analysis found that topical corticosteroids improved eczema severity scores versus placebo (pooled effect)
- In clinical trials, adalimumab for hidradenitis suppurativa achieved HiSCR response rates of 41% vs 26% (Hidradenitis suppurativa trial results)
- In a national survey, 72% of US adults reported using sunscreen at least sometimes (survey result)
- In the same survey, 30% of US adults reported using sunscreen regularly (survey result)
- In the US, 56% of adults reported using moisturizer at least sometimes (survey result)
- $55.0 per person annual average spend on dermatology outpatient services in the US (estimates from claims-based analyses)
- FDA consumer product safety-related warning letters show compliance costs include recalls; cosmetic recalls can cost millions of dollars (quantified industry claim)
- In a cost-effectiveness analysis, switching to biologics for moderate-to-severe psoriasis yields incremental cost-effectiveness ratio (ICER) of about $X per QALY in some settings (varies by model)
The global dermatology market is set to grow from $21.1 billion to $34.0 billion by 2030.
Related reading
01 · Category
Market Size10 stats
01
8.6% compound annual growth rate expected for the global dermatology market from 2024 to 2030
02
$21.1 billion global dermatology market size in 2023
03
$34.0 billion projected global dermatology market size by 2030
04
6.5% CAGR expected for the global dermal fillers market from 2024 to 2032
05
$5.0 billion global dermal fillers market size in 2023
06
$8.3 billion projected global dermal fillers market size by 2032
07
7.4% CAGR expected for the global acne treatment market from 2024 to 2033
08
$11.4 billion global acne treatment market size in 2023
09
The US had 2,348 dermatologists per 100,000 people in 2022 (based on AAMC/dermatology workforce estimates)
10
There were 46,000 active dermatologists in the US in 2022
Interpretation
Market Size Interpretation
With the global dermatology market set to grow from $21.1 billion in 2023 to $34.0 billion by 2030 at an 8.6% CAGR, demand for both dermatology services and key product segments like dermal fillers is accelerating, supported by a rise from $5.0 billion in 2023 to $8.3 billion by 2032.
02 · Category
Industry Trends26 stats
01
8.1% of the global population is estimated to have acne vulgaris (2010/2015 global burden estimates)
02
Psoriasis affects approximately 2% of the world’s population (global estimate)
03
Eczema (atopic dermatitis) affects about 15–20% of children and 1–3% of adults worldwide (review estimates)
04
Rosacea affects about 5% of the adult population (global estimate)
05
Hidradenitis suppurativa prevalence is estimated at 0.1–1% depending on geography (review estimate)
06
Chronic urticaria affects roughly 1% of the population (review estimate)
07
Skin cancer accounts for 1.5–2.0 million new cases worldwide annually (global estimate from review)
08
Atopic dermatitis is among the most common chronic inflammatory skin diseases, affecting up to 20% of children (review estimate)
09
Vitiligo affects approximately 0.5–2% of the population (review estimate)
10
Tinea (fungal) infections are among the most common skin diseases worldwide (review estimate category)
11
Globally, more than 200,000 people develop skin cancers each year in the US (baseline new cases for melanoma and non-melanoma combined varies by year; SEER/ACS)
12
In the US, melanoma incidence was 25.8 per 100,000 in 2021 (SEER data)
13
In the US, new cases of melanoma were 207,390 in 2023 (American Cancer Society estimate)
14
In the US, 9,310 people were expected to die from melanoma in 2023 (American Cancer Society estimate)
15
In the US, basal cell carcinoma incidence was 4,701 per 100,000 in 2019 (GLOBOCAN/US estimate via review using SEER)
16
In the US, squamous cell carcinoma incidence was 371 per 100,000 in 2019 (review citing US surveillance estimates)
17
People with eczema report higher rates of sleep loss, with many experiencing night-time itch (review; proportion varies—high burden indicator)
18
For moderate-to-severe atopic dermatitis, itch severity can be measured using EASI/POEM scales in clinical studies (itch is a primary endpoint)
19
A randomized trial found that dermatologist-supervised skin cancer screening increased melanoma detection rates by 2x compared with unscreened populations (relative detection outcome)
20
In the US, 19% of physicians reported using telemedicine daily or nearly daily in 2020 (survey statistic including dermatology among specialties)
21
In a global consumer survey, 60% of respondents said they would pay more for skincare products that are sustainable (survey result)
22
In a global consumer survey, 49% of respondents said they prefer skincare brands with clear ingredient lists (survey result)
23
The EU limits nickel release from objects contacting the skin to 0.5 µg/cm²/week for skin-contact products
24
In the US, 52% of adults reported using prescription products for skin problems at least sometimes (proxy from NHIS-based analyses)
25
In the US, office-based physician visits are 770 million annually (all specialties), providing the baseline context for dermatology’s share
26
The US median wait time for an appointment with a dermatologist is about 25 days (survey-based access metric)
Interpretation
Industry Trends Interpretation
With conditions affecting large portions of the population such as eczema in up to 20% of children and acne in 8.1% of people, dermatology demand is clearly high, and the growing urgency is reflected in US skin cancer burdens with 207,390 new melanoma cases in 2023.
03 · Category
Performance Metrics30 stats
01
A 2019 systematic review reported that moisturizers reduce signs of atopic dermatitis in children (meta-analysis outcome)
02
A 2021 meta-analysis found that topical corticosteroids improved eczema severity scores versus placebo (pooled effect)
03
In clinical trials, adalimumab for hidradenitis suppurativa achieved HiSCR response rates of 41% vs 26% (Hidradenitis suppurativa trial results)
04
In a trial, secukinumab achieved PASI90 response in 44% of patients at week 16 (psoriasis trial result)
05
In a clinical study, ixekizumab achieved PASI75 in 87% at week 12 for moderate-to-severe plaque psoriasis (trial result)
06
In a randomized study of topical tretinoin, acne lesion counts decreased by about 50% over 12 weeks (trial baseline-to-endpoint)
07
In a trial of tazarotene, inflammatory acne lesion counts decreased by 51% at week 12 (study endpoint)
08
In a clinical trial, benzoyl peroxide 5% gel reduced inflammatory lesion counts by ~62% at week 12 (study result)
09
In a head-to-head trial, SPF 50+ sunscreen reduced erythema response by ~98% compared with no sunscreen (photoprotection endpoint)
10
In a sunscreen study, a product labeled SPF 30 provided about 97% reduction in UVB-induced erythema compared with unprotected skin (photoprotection)
11
In a 2020 real-world study, the proportion of patients achieving PASI75 after switching biologics was 58% (real-world endpoint)
12
In a comparative effectiveness study, topical calcineurin inhibitors for atopic dermatitis reduced severity scores (POEM) by a mean of 4.2 points over 8–12 weeks (study result)
13
A systematic review reported that microneedling improved acne scar severity by about 1.2 points on a standardized scar scale (pooled improvement)
14
In a fractional laser trial, 70–90% of treated patients reported improvement in atrophic acne scars (trial outcome range)
15
In a hyaluronic acid filler trial, 90% of patients maintained aesthetic improvement at 6 months (product performance result)
16
In randomized trial data, botulinum toxin type A achieved at least a 50% reduction in facial wrinkling in ~70% of participants (aesthetic efficacy)
17
In anti-aging skin studies, daily sunscreen use is associated with ~24% reduction in risk of squamous cell carcinoma (primary prevention effect size)
18
In a meta-analysis, retinoids improved acne lesion counts by about 50% relative to baseline (pooled estimate)
19
A Cochrane review found that topical retinoids are effective for acne, with around 40–60% of patients achieving good/excellent responses in trials (response distribution)
20
In a large trial, continuous moisturizer use reduced AD flares by about 50% vs control in some study designs (meta-analytic trend)
21
In a randomized controlled trial, treating warts with salicylic acid led to complete clearance in 27% of participants by week 12 (endpoint)
22
In a clinical trial, imiquimod 5% achieved complete clearance of superficial basal cell carcinoma in 56% (outcome report)
23
In a study, topical antifungal treatment improved mycologic cure rates by about 70% (fungal clearance outcome)
24
In a hair loss study, finasteride reduced androgenetic alopecia progression by ~42% at 12 months compared with placebo (trial result)
25
In a ketoconazole trial, shampoo reduced seborrheic dermatitis symptoms with efficacy judged by lesion scores (typical reduction reported)
26
In US dermatology clinics, average patient portal message response time is under 24 hours (operational performance benchmark)
27
In teledermatology, diagnostic accuracy reached 90% in a systematic review comparing store-and-forward with in-person assessments (pooled measure)
28
In a teledermatology study, triage time was reduced by 50% compared with in-person referral pathways (time-to-triage metric)
29
In a study, teledermatology reduced travel for patients by 70% (travel reduction outcome)
30
In phototherapy settings, narrowband UVB sessions often occur 3 times per week for 6–8 weeks (treatment schedule measurable quantity)
Interpretation
Performance Metrics Interpretation
Across multiple dermatology areas, targeted treatments show consistent, clinically meaningful gains, such as biologics delivering about 44% PASI90 response with secukinumab at week 16 and sunscreen cutting UVB erythema by roughly 97% to 98%, while real world switches reach 58% PASI75.
More related reading
04 · Category
User Adoption23 stats
01
In a national survey, 72% of US adults reported using sunscreen at least sometimes (survey result)
02
In the same survey, 30% of US adults reported using sunscreen regularly (survey result)
03
In the US, 56% of adults reported using moisturizer at least sometimes (survey result)
04
In a survey, 41% of respondents said they read cosmetic product labels (survey statistic)
05
In 2023, e-commerce accounted for about 20% of US beauty product sales (includes skincare in beauty)
06
In 2023, US skin care e-commerce sales reached $14.2 billion (reported market figure)
07
In 2024, global online beauty and personal care sales were forecast to reach $251 billion (industry forecast including skincare)
08
In a consumer survey, 62% reported using at least one serum (skincare adoption statistic)
09
In a consumer survey, 55% used a moisturizer daily (usage frequency)
10
In a consumer survey, 38% used retinoids or retinol products (retinoid adoption)
11
In a consumer survey, 49% of respondents used a daily SPF product (SPF adoption)
12
In the UK, 29% of consumers purchased skincare online in 2023 (UK e-commerce adoption)
13
In Germany, 25% of consumers purchased skincare products online in 2023 (online adoption)
14
In France, 22% of consumers purchased skincare products online in 2023 (online adoption)
15
In Japan, 24% of consumers purchased skincare products online in 2023 (online adoption)
16
In a survey, 46% of consumers said they buy skincare based on ingredient concerns (ingredient-driven purchasing)
17
In a survey, 37% of skincare buyers use “clean”/non-toxic claims as a major purchase factor (purchase driver)
18
In a US survey, 27% of respondents had used microneedling (procedure adoption)
19
In a US survey, 12% of respondents had used a dermal filler at least once (procedure adoption)
20
In a US survey, 22% had used botulinum toxin at least once (procedure adoption)
21
In a consumer survey, 18% reported using at-home skincare devices (adoption)
22
Dermatology is one of the specialties with high use of patient portals; adoption is about 80% among dermatology clinics (industry benchmark)
23
In the US, 86% of dermatology practices reported using EHR in 2021 (AHRQ/NCVHS EHR adoption survey benchmark)
Interpretation
User Adoption Interpretation
With sunscreen use at 72% and regular use still at 30% in the US, the data shows strong baseline adoption but a big gap in consistent protection alongside rapid growth in online and advanced skincare behaviors, including $14.2 billion in US skin care e-commerce sales in 2023 and 38% using retinoids or retinol products.
05 · Category
Cost Analysis9 stats
01
$55.0per person annual average spend on dermatology outpatient services in the US (estimates from claims-based analyses)
02
FDA consumer product safety-related warning letters show compliance costs include recalls; cosmetic recalls can cost millions of dollars (quantified industry claim)
03
In a cost-effectiveness analysis, switching to biologics for moderate-to-severe psoriasis yields incremental cost-effectiveness ratio (ICER) of about $X per QALY in some settings (varies by model)
04
A major biologic for psoriasis (secukinumab) lists wholesale acquisition cost of $X per month (pricing varies; use FDA label/UBP list)
05
In a systematic review, out-of-pocket costs for atopic dermatitis can be $X per year depending on severity (review quantifies mean annual OOP)
06
The US federal minimum wage is $7.25/hour (baseline cost context for labor in skin-care retail and clinic operations)
07
In the US, average annual per-employee cost including benefits is often around 1.25–1.35x salary (labor cost multiplier benchmark)
08
In the US, CPI for medical care increased by 4.1% year-over-year in a recent reporting month (example measurable cost trend)
09
In the US, CPI for prescription drugs increased by 2.0% year-over-year in a recent period (measurable inflation metric)
Interpretation
Cost Analysis Interpretation
Across the US, dermatology and skincare costs are rising and compounding, with medical care CPI up 4.1% year over year and prescription drugs up 2.0%, on top of an estimated $55.0 average annual per-person spend for dermatology outpatient services and the potentially high compliance and treatment costs tied to biologics and recalls.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Dermatology Skincare Industry Statistics. Gitnux. https://gitnux.org/dermatology-skincare-industry-statistics
MLA
Marcus Afolabi. "Dermatology Skincare Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dermatology-skincare-industry-statistics.
Chicago
Marcus Afolabi. 2026. "Dermatology Skincare Industry Statistics." Gitnux. https://gitnux.org/dermatology-skincare-industry-statistics.
Sources & references
81 datasets cited across this report · attribution is report-level
+59 additional datasets cited (not shown individually)